How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?

When using azacitidine for the treatment of MDS, I adjust the dose in case of cytopenia for cycle 2 onwards.

• If there was no baseline cytopenia (ANC >1.5, PLT >75K) but cytopenia developed with treatment, the subsequent cycle is delayed until counts recover, and the dose is based on the nadir and t...